Nuvig Therapeutics Announces $161 Million Series B Financing and Progression to Phase 2 Development with Novel, Second-Generation Immunomodulator
December 5, 2025Arialys Therapeutics Publishes Preclinical Data in Nature Communications Supporting ART5803 as a First-in-Class Precision Therapeutic for Anti-NMDA Receptor Autoimmune Neuropsychiatric Disease
June 17, 2025Casma Therapeutics Nominates CSM-101 as a Development Candidate for the Treatment of Rare and Common Forms of Parkinson’s Disease
June 5, 2025TRexBio Doses First Participant in Phase 1 Trial of TRB-061, a Novel TNFR2 Agonist for Atopic Dermatitis and Other Inflammatory Diseases
June 3, 2025Sail Biomedicines to Present New Preclinical Data on Malaria eRNA™ Vaccine Candidates at the 2025 Grand Challenges Annual Meeting
June 2, 2025ProteinQure Raises Series A Financing to Advance First AI-Designed Peptide Therapeutic into Clinical Trials
May 28, 2025- See All Press Releases
